AIO INTEGA Provides Further Support for Immunotherapy in Patients With Advanced ERBB2-Positive Gastroesophageal Adenocarcinoma

Monica Patel^{1

2}, Nataliya Uboha^{1

2}

Affiliations

¹ Division of Hematology, Medical Oncology and Palliative Care, Department of Medicine, University of Wisconsin, Madison.
² Carbone Cancer Center, Madison, Wisconsin.

Comment

Monica Patel et al. JAMA Oncol. 2022.

. 2022 Aug 1;8(8):1158-1159.

doi: 10.1001/jamaoncol.2022.2008.

Monica Patel^{1

2}, Nataliya Uboha^{1

2}

¹ Division of Hematology, Medical Oncology and Palliative Care, Department of Medicine, University of Wisconsin, Madison.
² Carbone Cancer Center, Madison, Wisconsin.

No abstract available

Comment on

Efficacy of Ipilimumab vs FOLFOX in Combination With Nivolumab and Trastuzumab in Patients With Previously Untreated ERBB2-Positive Esophagogastric Adenocarcinoma: The AIO INTEGA Randomized Clinical Trial.
Stein A, Paschold L, Tintelnot J, Goekkurt E, Henkes SS, Simnica D, Schultheiss C, Willscher E, Bauer M, Wickenhauser C, Thuss-Patience P, Lorenzen S, Ettrich T, Riera-Knorrenschild J, Jacobasch L, Kretzschmar A, Kubicka S, Al-Batran SE, Reinacher-Schick A, Pink D, Sinn M, Lindig U, Hiegl W, Hinke A, Hegewisch-Becker S, Binder M. Stein A, et al. JAMA Oncol. 2022 Aug 1;8(8):1150-1158. doi: 10.1001/jamaoncol.2022.2228. JAMA Oncol. 2022. PMID: 35737383 Free PMC article. Clinical Trial.